Table 11.
American College of Rheumatology (ACR) criteria scores of 20, 50, and 70 network meta-analysis base case results for monotherapy treatments in DMARD-experienced patients: licensed DMARD monotherapy versus placebo
| Fixed effect | Random effects | |||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| OR v PLA (95% CrI) | % of patients with event (95% CrI) | Probability of best, % | OR v PLA (95% CrI) | % of patients with event (95% CrI) | Probability of best, % | |
| ACR 20 | ||||||
| PLA | – | 14.1% (11.1%, 17.7%) | 0.0% | – | 14% (11.1%, 17.7%) | 0.0% |
| ADA 40 mg/2 weeks | 4.947 (3.163, 7.77)‡ | 44.8% (32.4%, 57.9%) | 7.1% | 5.125 (1.417, 18.62)‡ | 45.5% (18.5%, 75.7%) | 6.9% |
| ETN 2 × 25 mg/week | 11.85 (5.371, 29.52)‡ | 66% (45.6%, 83.4%) | 28.0% | 12 (1.733, 90.94)‡ | 66.3% (21.8%, 93.8%) | 23.6% |
| SUL | 1.598 (0.522, 5.172) | 20.8% (7.6%, 46.4%) | 0.0% | 1.608 (0.105, 27.48) | 20.7% (1.7%, 82%) | 0.4% |
| TOC 8 mg/kg/4 weeks | 26.17 (10, 76.19)‡ | 81.1% (61%, 92.8%) | 64.9% | 26.25 (3.883, 190.8)‡ | 81.1% (38.6%, 97%) | 69.2% |
| ACR 50 | ||||||
| PLA | – | 5.9% (3.9%, 8.7%) | 0.0% | – | 5.9% (3.9%, 8.7%) | 0.0% |
| ADA 40 mg/2 weeks | 4.818 (2.616, 9.344)‡ | 23.2% (12.5%, 39.8%) | 7.1% | 5.117 (1.819, 16.11)‡ | 24.3% (9.4%, 51.5%) | 6.9% |
| ETN 2 × 25 mg/week | 13.83 (4.745, 54.01)‡ | 46.4% (21.3%, 78.1%) | 28.0% | 13.46 (2.631, 80.29)‡ | 45.6% (13.3%, 84.1%) | 23.6% |
| SUL | 2.476 (0.58, 11.84) | 13.4% (3.3%, 43.7%) | 0.0% | 2.379 (0.241, 25.64) | 13% (1.4%, 62.7%) | 0.4% |
| TOC 8 mg/kg/4 weeks | 46.94 (7.572, 915.5)‡ | 74.7% (31.2%, 98.3%) | 64.9% | 55.08 (6.204, 1740)‡ | 77.5% (26.9%, 99.1%) | 69.2% |
| ACR 70† | ||||||
| PLA | – | 1.3% (0.6%, 3.1%) | 0.0% | – | 1.3% (0.5%, 3.1%) | 0.0% |
| ADA 40 mg/2 weeks | 11.42 (3.866, 44.01)‡ | 13.2% (3.6%, 42.8%) | 7.1% | 11.71 (2.441, 77.5)‡ | 13.5% (2.5%, 55%) | 6.9% |
| ETN 2 × 25 mg/week | 19.49 (3.199, 788.9)‡ | 20.9% (3.3%, 92%) | 28.0% | 20.83 (1.56, 1740)‡ | 21.8% (1.7%, 96%) | 23.6% |
| SUL | 1.042 (0.025, 57.47) | 1.4% (0%, 44.8%) | 0.0% | 1.14 (0.012, 178.8) | 1.5% (0%, 71.5%) | 0.4% |
| TOC 8 mg/kg/4 weeks | 55.54 (5.138, 6469)‡ | 43% (5.4%, 98.9%) | 64.9% | 96.27 (3.992, 38820)‡ | 56.1% (4.5%, 99.8%) | 69.2% |
Notes:
†
ACR 70 data with continuity correction;
‡
licensed monotherapy has significantly higher odds of ACR outcome compared to PLA (based on the 95% CrI).
Abbreviations: ADA, adalimumab; CrI, credible interval (Bayesian probability interval); DNC, did not converge; DMARD, disease-modifying antirheumatic drug; ETN, etanercept; exp, experienced; MTX, methotrexate; OR, odds ratio; PLA, placebo; SUL, sulfasalazine; TOC, tocilizumab.